Invivyd, Inc. (Nasdaq: IVVD) specializes in developing potent, virus-resistant medicines using a proprietary integrated technology platform. The company focuses on creating best-in-class antibodies through advanced assessment and adaptation techniques. In March 2024, Invivyd received emergency use authorization for a monoclonal antibody, highlighting its innovation in treating immune-compromised patients.
Invivyd, Inc. is seeking a Medical Director to oversee clinical trials and the development strategy for innovative antibody candidates. The role involves medical leadership, scientific input, and collaboration with multiple departments. The company is focused on protecting immunocompromised populations through the delivery of protection from serious viral infectious diseases.
Invivyd, Inc. (Nasdaq: IVVD) specializes in developing potent, virus-resistant medicines using a proprietary integrated technology platform. The company focuses on creating best-in-class antibodies through advanced assessment and adaptation techniques. In March 2024, Invivyd received emergency use authorization for a monoclonal antibody, highlighting its innovation in treating immune-compromised patients.
Kailera Therapeutics, Inc.